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The term angiogenesis describes the growth of endothelial sprouts from preexisting postcapillary venules. More recently, this term
has been used to generally indicate the growth and remodeling process of the primitive vascular network into a complex network
during development. In adulthood, angiogenesis is activated as a reparative process during wound healing and following ischemia,
and it plays a key role in tumor growth and metastasis as well as in inﬂammatory diseases and diabetic retinopathy. MicroRNAs
(miRNAs) are endogenous, small, noncoding RNAs that negatively control gene expression of target mRNAs. In this paper, we aim
at describing the role of miRNAs in postischemic angiogenesis. First, we will describe the regulation and the expression of miRNAs
in endothelial cells. Then, we will analyze the role of miRNAs in postischemic vascular repair. Finally, we will discuss the role of
circulating miRNAs as potential biomarkers in ischemic diseases.
1.Introduction
Postnatal neovascularization occurs in pathological diseases,
including diabetic retinopathy, arthritis, and tumor growth
and metastasis, as well as during wound healing and
postischemic repair [1]. Following occlusion of a major
artery, two diﬀerent types of vascular regrowth responses
are activated to contrast the ischemic condition and salvage
of injured ischaemic tissue: sprouting of capillaries (angio-
genesis) and growth of collateral arteries from preexisting
arterioles (arteriogenesis) [2]. Angiogenesis is the process of
growth of endothelial sprouts from preexisting postcapillary
venules. It is initiated by the vasodilation of venules leading
to increased permeability, followed by the proliferation
and migrationof endothelial cells (ECs). Then, venules are
divided by periendothelial cells (intussusception) or are
separated by transendothelial cell bridges (bridging) to form
capillaries [3, 4].
Arteriogenesis was originally deﬁned as the process of
collateral arteries formation which follows the occlusion
of a major artery [5]. Arteriogenesis is partly driven by
shear stress and involves the proliferation and migration of
vascular endothelial cells (ECs) and vascular smooth muscle
cells (VSMCs). It leads to the production of mature arteries
with a fully developed tunica media, which may provide
alternativebloodperfusiontoischemicareas[6].microRNAs
(miRNAs) are inhibitory regulators of gene expression which
act by binding to complementary messenger RNA (mRNA)
transcripts. Following initial studies in developmental biol-
ogy and cancer, miRNAs have recently come into focus
of cardiovascular diagnostics and therapeutics [7, 8]. Since
miRNAs repress many target mRNAs, deregulation of one
single miRNA can result in a cascade of transcriptional
and posttranscriptional changes relevant to disease states
[9]. miRNAs have been detected in serum and plasma, and
circulating miRNA proﬁles have now been associated with
cancer [10], diabetes [11], and heart disease [12]a sa n
emerging class of biomarkers. Here, we discuss the role of
miRNAs in postischemic angiogenesis.
2. MicroRNAs Biogenesis
Transcriptions of miRNA genes and protein-coding genes
share common regulatory mechanisms [13]. miRNA genes
can be embedded in the introns of protein coding genes
or can derive from their own transcript units in intergenic
regions of the genome. When miRNA genes are located2 Cardiology Research and Practice
withinintronsofprotein-codinggenes,primarymiRNAbio-
genesis is controlled by the same transcriptional mechanisms
as the parent gene. In contrast, an independent miRNA
gene will have its own transcriptional controls. Interestingly,
multiple miRNAs can be produced within a single long
primary nuclear miRNA transcript (pri-miRNA transcript),
each of which can act independently [14, 15]. The long
primary nuclear miRNA transcript (“pri-miRNA”) under-
goes maturation by the RNase-III Drosha/Dgcr8 enzyme
complex,generatingaprecursormiRNA(“pre-miRNA”)that
isexportedfromthenucleusbyexportin-5[16].Cytoplasmic
pre-miRNAs are cleaved by a Dicer-containing complex
[17] to generate a double-strand miRNA-duplex containing
the mature miRNA on one strand and a complementary
miRNA∗ on the other strand. Recently, Dicer-independent
miRNA biogenesis pathway has also been reported [18].
The speciﬁcity of miRNA targeting is deﬁned by Watson-
Crick complementarities between positions 2 to 8 from the
5  miRNA (also known as the seed sequence), with the
3  untranslated region (UTR) of their target mRNAs [15].
Besides the binding through 3  UTR interactions, some
miRNAs have been shown to associate to the open reading
frame or to the 5  UTR of the target genes [19]. miRNAs
act through formation of stable complexes with proteins
of the Argonaute (Ago) family (in particular with Ago2),
the core of the RNA-induced silencing complex (RISC).
The RISC blocks the translation initiation by competition
with the cytoplasmic cap-binding protein eIF4E (eukaryotic
translation initiation factor 4E) [20] or the antiassociation
factor eIF6, thus preventing the assembly of the ribosome
[21]. Besides these mechanisms, RISC-miRNA complexes
canmovethemRNAstheybindtothe“P-bodies,”specialized
cytoplasmic compartments enriched in mRNA-catabolizing
enzymes, where translational repression or exonucleolytic
mRNA degradation or mRNA destabilization may occur
[22, 23].
3. ExpressionandRegulation of
MicroRNAs inEndothelial Cells
miRNA microarray analysis is, at the moment, the most used
and complete technique to analyse global miRNAs expres-
sion proﬁle. Using this approach, 28 miRNAs (miRNA-15b,
-16, -20, -21, -23a, -23b, -24, -27a, -29a, -30a, -30c, -31, -
100, -103, -106, 125a and -b, -126, -181a, -191, -199a, -221,
-222, -320, let-7, let-7b, let-7c, and let-7d) have been found
to be commonly expressed in ECs cultured under normal
conditions [24–30]. The miRNA expression proﬁle in ECs
could change if cells are studied under stressed conditions,
as we recently proved for miRNA-503 (miR-503), which is
induced in ECs in response to diabetes and ischemia [31]. A
highly scalable approach using next generation sequencing
(small RNA-seq) would facilitate the analysis of miRNA
expression patterns in ECs. The group of Martelli was the
ﬁrst to use this approach to analyze the miRNAs expressed
by ECs exposed to hypoxia [32]. Based on experimental
evidence, it is possible to divide the endothelial miRNAs into
pro- and antiangiogenic miRNAs (Table 1).
Table 1: microRNAs and target genes involved in neovascularisa-
tion.
Proangiogenic
miRNAs Target genes References
miR-126 Spred1/PIK3R2 [33]
miR-221/222 c-kit [34]
miR-378 Fus-1/Sufu [35]
miR-424 CUL2 [36]
miR-132 p120RasGAP [37]
miR-210 EFNA3 [27]
miR-130a Spred1/PIK3R2 [38]
miR-296 c-kit [28]
miR-17-5p Fus-1/Sufu [39]
miR-23-27 CUL2 [40]
Antiangiogenic
miRNAs Target genes References
miR-200c ZEB1 [41]
miR-217 SIRT1 [42]
miR-34 SIRT1 [43]
miR-503 CCNE1/cdc25A [31]
miR-20a VEGF-A [44]
miR-92a ITGB5 [45]
miRNAs involved in
postischemic
angiogenesis
Ischemic stimuli miRNAs References
Myocardial infarct miR-126 [33]
Myocardial infarct
Peripheral ischemia miR-92a [45]
Myocardial infarct miR-210 [46].
Peripheral ischemia miR-503 [31]
Peripheral ischemia miR-92a [45]
Myocardial infarct miR-’100 [47]
3.1. Proangiogenic MicroRNAs. miR-126 is recognized as the
most important miRNA for maintaining vascular integrity
during ongoing angiogenesis, as it targets SPRED1 and
PIK3R2, two negative regulators of VEGFs signalling [30,
33]. Angiogenic sprouting of vessels requires that the zinc
ﬁnger transcription factor klf2a induces expression of an
endothelial-speciﬁc miR-126 [48]. Growth factors increase
the expression of the pro-angiogenic miR-130a and miR-
296 in ECs [28, 38]. miR-130a stimulates angiogenesis by
inhibiting GAX and HOXA5; while, miR-296 acts through
the inhibition of hepatocyte growth factor (HGF)-regulated
tyrosine kinase [28]. Moreover, EC stimulation with VEGF-
A and bFGF lead to a rapid transcription of miR-132.
Overexpression of miR-132 increases EC proliferation and
in vitro networking by targeting p120RasGAP, a GTPase-
activating protein [49]. miR-210 overexpression consider-
ably increased HUVEC migration and the formation ofCardiology Research and Practice 3
capillary-like structures by targeting ephrin A3 [27]. miR-
424promotesangiogenesisbyinhibitingcullin2(CUL2)and
thereby increasing HIF-1α levels [36]. The proangiogenesis
activity of the miR-17–92 cluster is due to miR-17-5p, miR-
18a, and miR-19a [26]. In fact, the latter two miRNAs have
been shown to target proteins containing thrombospondin
type 1 repeats (TSR) [26, 50]; while miR-17-5p appears to
modulate EC migration and proliferation by targeting tissue
inhibitor of metalloproteinase 1 (TIMP1) [39]. Recently,
the miR-23-27-24 cluster has also been reported to have
a prominent role in angiogenesis [40]. In particular, both
miR-23 and miR-27 enhance angiogenesis by targeting
the anti-angiogenic proteins Sprouty2 and Sema6A [40].
Finally, miR-378 promotes angiogenesis by targeting tumor
suppressor candidate 2 (Fus-1) and suppressor of fused
(Sufu), thus inducing indirect up-regulation of VEGF and
Angiopoietin-1/2 [35].
3.2. Antiangiogenic MicroRNAs. The antiangiogenic miR-
221/222 was discovered by Poliseno et al. during the ﬁrst
screening of miRNAs in HUVECs [34]. Overexpression of
miR-221/222 inhibits the angiogenesis responses to stem
cell factor (SCF) by targeting the SCF receptor c-kit [34].
Belonging to miR-17-92 cluster, miR-20a, and miR-92a dis-
play antiangiogenenic activity, respectively, targeting VEGF-
A and integrin β5( I T G B 5 )t r a n s c r i p t s[ 44, 45]. Oxidative
stress upregulates miR-200c in ECs, which translates in
the downmodulation of the miR-200c target ZEB1 [41].
miR-217 and miR-34 regulate the expression of silent
information regulator 1 (SirT1). Inhibition of either miR-
217 or miR-34 in ECs promotes angiogenesis via an increase
in SirT1 activity [42, 43]. Finally, miR-503 expression
in ECs is upregulated under anti-angiogenic conditions
mimicking diabetes mellitus and ischemia [31]. miR-503
targets cdc25A and cyclinE1 (CCNE1) and its overexpression
inhibitsEC proliferation, migration, and network formation
on Matrigel. Conversely, blocking miR-503 activity restores
the angiogenic process in diabetic and ischemic limb mus-
cles. [31].
4. MicroRNAs inPostischemic Angiogenesis
Ischaemic disease is highly prevalent and is associated
with elevated morbidity and mortality in developed and
developing countries [51]. Functional recovery of ischemic
tissues and organs is dependent on establishing collateral
networksthatsupplyoxygenatedblood[52,53].Therapeutic
inductionofangiogenesismayattenuateischemicsuﬀerance.
Notwithstanding, despite the remarkable results in animal
models of limb ischemia and myocardial infarct, the results
of 15 years of clinical trials with monotherapeutic proan-
giogenic agents have been unsatisfactory [54]. One of the
reasons accounting for this failure is that monotherapy may
benotsuﬃcienttopromoteandmaintainafunctionalvascu-
larnetworkunderseverelycompromisedmedicalconditions.
Thus, one alternative therapeutic approach could consist of
drug combinations in order to promote angiogenesis and
vascular maturation and stabilization [55]. Because each
miRNA has multiple targets, modulating the expression
of one miRNA could impact on the complex molecular
pathways governing ischemic complications by potentially
increasing the expression and/or activity of multiple growth
factors. Hence manipulation of miRNAs could represent a
novel technology potentially able to interfere with expres-
sional regulation of multiple genes, thus opening new
avenues for molecular therapeutics (Figure 1).
4.1. Limb Ischemia. Peripheral artery disease (PAD) induces
limb muscle hypoperfusion and favours the formation and
aggravation of skin ulcers. When the wound healing capacity
is lost, PAD patients progress to a critical condition, identi-
ﬁed as critical limb ischaemia (CLI), which usually requires
minor or major amputations of the aﬀected limb [56].
Despite improvements in surgical treatments, a signiﬁcant
portionofpatientswithCLIarenoteligibleforrevasculariza-
tion,andnomedicaltherapyhasbeenshowntobecapableof
reducing the need for amputation [57]. Diabetes aggravates
PADandCLI.Furthermore,postischemicrecoveryisdelayed
in diabetic patients due to diabetes-induced impairment of
reparative angiogenesis. A laboratory-based study showed
that conditional inactivation of Dicer in ECs reduced the
spontaneous angiogenic responses to limb ischemia, demon-
strating that endothelial miRNAs are required for reparative
neovascularisation [26]. Recently, miRNA expression in
murine models of limb ischemia has been proﬁled, showing
upregulation of miR-92a and -100 [47, 58]. miR-92 represses
the ITGB5 target gene, thus impairing angiogenesis both
in vitro and in vivo [45]. Conversely, miR-100 functions
as an endogenous repressor of the serine/threonine protein
kinase mammalian target of rapamycin (mTOR), increasing
EC proliferation, sprouting activity and network formation
on Matrigel [47]. Moreover, we found miR-503 levels to be
remarkably higher in ischemic muscles of diabetic mice and
of diabetic patients with CLI in comparison to nondiabetic
and/or nonischemic controls [31]. In summary, it is evident
that a number of miRNAs are modulated by ischemia and
participate in postischemic angiogenesis.
4.2. Acute Myocardial Infarction. Myocardial ischemic injury
results from severe impairment of the coronary blood supply
usually produced by thrombosis or other acute alterations
of coronary atherosclerotic plaques. Rapid formation of
collateral vessels that bypass the obstructed coronary artery
is necessary for the survival of the myocardial region that
surrounds the necrotic infarct tissue and for the subsequent
myocardial repair process.
The most convincing data in the cardiac response to
ischemia areformiR-126, miR-210, and miR-92a. Neovascu-
larization at 3 weeks postmyocardial infarct (MI) is inhibited
in miR-126 knockout mice in comparison with wild type
[33]. Moreover, miR-126 is downregulated in the MI area,
but upregulated in the MI border zone [33]. In contrast,
miR-210 is upregulated in the ischemic myocardium [46].
miR-210 expression is induced by HIF1α, and it has been
associated with increased survival of cardiomyocytes and
increased angiogenesis in a murine model of myocardial4 Cardiology Research and Practice
Critical limb ischemia
(CLI)
Myocardial infarction
(MI)
Anti-miR-503
Anti-miR-92a
Anti-miR-92a
Anti-miR-100
miR-mimics 210
miR-503 inhibition restores post
ischemic angiogenesis in ischemic and
diabetic limb muscle
miR-92a inhibition enhances myocardial
neovascularization after limb ischemia
miR-100 inhibition stimulates
angiogenesis and improve perfusion
after femoral artery occlusion
miR-92a inhibition enhances myocardial
neovascularization after MI
miR-210 overexpression increases
myocardial neovascularization after MI
Figure 1: miRNAs-based therapeutic strategies in vascular repairs, There are two major approaches to developing miRNA-based
therapeutics: miRNA antagonists and miRNA mimics. miRNA antagonists are generated to inhibit endogenous miRNAs that show a
pathogenic gain-of-function in diseased tissues. miRNA mimics are used to upregulate expression of beneﬁcial miRNAs. Inhibition of miR-
92a, miR-100 and miR-503 or increase of miR-210 can promote angiogenesis, thus improving postischemic blood ﬂow recovery in limb
ischemia or myocardial infarction.
infarction [46]. Finally, miR-92a expression increases after
experimental MI and inhibits neovascularisation [45].
4.3. miRNAs-Based Therapeutic Strategies in Vascular Repair.
There are two major approaches to developing miRNA-
based therapeutics: miRNA antagonists and miRNA mimics.
miRNA mimics are small, chemically modiﬁed, double-
stranded RNA molecules that mimic endogenous mature
miRNA molecules. Mimics of proangiogenic miRNAs can
be used to elevate angiogenesis in the pathological setting of
insuﬃcient angiogenesis, such as cardiac and limb ischemia.
Caution should be used when overexpressing miRNAs, as
an above physiological abundance of a miRNA could result
in “oﬀ-target eﬀects” through the miRNA binding to seed
regions of genes not normally targeted [8]. miRNAs can be
overexpressed by using naked oligodeoxynucleotides or viral
vectors.Recently,genetherapyusingaminicircleDNAvector
encoding the miR-210 precursor was shown to enhance
myocardial neovascularization in mice with MI [59].
Anti-miRNAs (antimiRs) are modiﬁed antisense oli-
godeoxynucleotides harboring the full or partial comple-
mentary reverse sequence of a mature miRNA. These oli-
godeoxynucleotides are able to reduce the endogenous levels
of the miRNA, thus increasing expression of its mRNA
targets [60]. Most common chemical modiﬁcations to
increase antimiR stability are LNA- (locked nucleic acid-)
modiﬁed nucleotides, in which the 2 -O-oxygen is locked
into a C3 -endo (RNA) sugar conformation [61]o ra
complete 2 -O-methylation of sugar in a phosphorothioate
backbone, and a cholesterol molecule at the 3  end. These
are the so-called “antagomiRs” [62]. LNA-antimiR against
miRNAs of the cluster miR-23/24 showed regulation of
angiogenesisandchoroidalneovascularisation[40].Systemic
delivery of antagomiR was shown to be suﬃcient to induce
eﬃcient and long-lasting miRNA inhibition in vivo and to
modulate neovascularization [45, 47, 63]. In particular, in
vivo miR-100 inhibition by speciﬁc antagomiRs stimulated
angiogenesis and resulted in functional improvement of
perfusion after femoral artery occlusion in mice [47]. Sim-
ilarly, antagomiR-induced inhibition of miR-92a enhanced
blood vessel repair in murine models of limb ischemia
and MI. [45, 47, 63]. Finally, miRNAs expression could be
inhibited using “miRNA sponge” or “decoy.” Typical sponge
constructscontainfourtotenmiRNAbindingsitesseparated
by a few nucleotides each to avoid Ago2-mediated endonu-
cleolytic cleavage [64, 65]. By this technique, we inhibited
miRNA-503 in the ischemic hindlimb of diabetic mice.
This anti-miRNA-based intervention restored postischemic
angiogenesis in ischemic and diabetic limb muscles [31].
5.CirculatingMicroRNAs
The discovery of miRNAs in biological ﬂuids is opening
new frontiers in the miRNA arena. Mitchell et al. ﬁrst
demonstrated that circulating miRNAs could be detected
reliably in serum and showed that miRNA proﬁles correlate
with speciﬁc diseases. Moreover, miRNAs appear protected
from RNAse and remain stable in the blood [66]. Therefore,
their stability makes miRNAs concentrations well suited for
being tested in patient samples as potential biomarkers of
diﬀerent pathological conditions. Recent studies identiﬁed
miRNAs in diﬀerent types of microvescicles (MVs) secreted
from cultured cells, thus supporting the idea that MVs may
s e r v ea sp h y s i o l o g i c a lc a r r i e r so fm i R N A[ 11, 67, 68]. In line
with this hypothesis, MVs released from cells were proved
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in vitro and in vivo by transferring miRNAs [69, 70]. Two
distinct processes of MVs release from the cells have been
described. MVs may derive from the endosomal membranes
that are extruded from the cell surface of activated cells
as exosomes [71]. Furthermore, high-density lipoprotein
(HDL) transports endogenous miRNAs and delivers them
to recipient cells with functional targeting capabilities [72].
Interestingly, a recent study demonstrated that the majority
of circulating miRNAs are complexed with protein rather
than with vesicles. In particular, Ago2 was present in human
plasma and eluted with plasma miRNAs. This ﬁnding raises
the possibility that cells release a functional RISC complex
into the circulation [73].
Recent reports suggest that serum levels of cardiac
miRNA correlate with the severity of heart injury and may
represent a good biomarker of MI. Corsten et al. described
strikingly increased plasma levels of miR-208b and -499 after
MI.However,studiesoncirculatingmiRNAsandMIhaveled
tocontrastingconclusionsonmiR-208.Wangetal.suggested
miR-208 as a candidate biomarker for MI in humans [74],
while Adachi et al. found very low levels of miR-208a
and miR-208b in human hearts [75]. The latter result was
conﬁrmed by D’Alessandra et al., who reported that miR-
208 was detectable only in 30% of MI patients and always
at very low levels [76]. In contrast, miR-499 was detectable
in all control subjects and increased in all patients with MI
[76]. Finally, we found that the plasma levels of miR-503
were dramatically increased in diabetic patients with CLI in
comparisonwithcontrols.Duetothelownumberofpatients
in the study, further analysis is required to investigate miR-
503 as a potential circulating biomarker of ongoing ischemia
in diabetic subjects [31].
6.FutureResearch
Great interest focuses on exploiting miRNAs for therapeutic
purposes and as clinical biomarkers. As therapeutic targets
forvasculardiseases,miRNAscouldrepresentamajorbreak-
through because a single miRNA can regulate several target
genes, thus inﬂuencing multiple molecular pathways. In
consideration of the above, miRNAs antagonists or mimics
could become an important new class of drugs to regulate
angiogenesis. Moreover, manipulation of miRNAs structures
might increase their delivery eﬃciency. In particular, the
promising results obtained with modiﬁed microparticles or
nanoparticles for drug delivery in cancer [37] should be
extended to investigate their capacity for promoting vascular
regeneration in ischemic tissues. A potential drawback in
the therapeutic use of miRNAs is their possible “oﬀ-target
eﬀects.” Since not all targets of a particular miRNA are
disease-related, any therapeutic perturbation of miRNA
expression will likely have side eﬀects.
Asbiomarkers,circulatingmiRNAsoﬀeragreatpotential
for the diagnosis and prognosis of diﬀerent diseases. How-
ever, there are still limitations in the technology and various
issues regarding miRNA measurement and quantiﬁcation
in the circulation. First, circulating miRNA proﬁling has
to be veriﬁed in larger and independent studies in order
to translate the ﬁndings into clinical biomarker. Then, in
order to obtain reliable and reproducible results, there is
a need to determine suitable normalization methods for
blood-based miRNA investigations. Finally, the mechanisms
by which miRNAs are released into the circulation and
whether circulating miRNA molecules have any functional
capabilities need further characterization.
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